Recruiting

Egg White Protein

Sponsor:

Seven Oaks Hospital Chronic Disease Innovation Centre

Code:

NCT06343727

Conditions

Kidney Failure

Frailty

Kidney Disease, Chronic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Egg white protein pudding

: Ensure Plus

Study Details

Brief summary:

The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are:

  • To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible.
  • To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements.
  • To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks.

Conditions

Kidney Failure

Frailty

Kidney Disease, Chronic

Study ID

NCT06343727

Start date

Jul 25, 2025

Status verified date

Apr, 2026

Completion date

Oct 1, 2026

Anticipated

Primary completion date

Aug 11, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the trial
  • Male or female aged ≥18 years with CKD
  • On chronic in-center hemodialysis for > 3 months
  • Serum albumin <35 g/L
  • No expected change in dialysis modality or relocation outside of Winnipeg during the intervention period (12 weeks)

Exclusion Criteria:

  • Allergy to eggs
  • History of renal transplant
  • Serum albumin ≥ 35 g/L
  • Bowel diseases
  • Cancer
  • Pregnancy
  • Receiving chemotherapy treatment
  • Inability to consume treatment product
  • Allergy to study treatment ingredients
  • Planning on starting an exercise program during the duration of the trial
  • Inability to obtain written informed consent

Study Design

Enrollment

54 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Egg white protein pudding

Participants will receive egg white pudding at the end of their dialysis treatments 3-days per week.

active comparator: : Standard dietary supplement

Participants will receive Ensure Plus at the end of their dialysis treatments 3-days per week.

Interventions

Egg white protein pudding

Will consume one egg white protein pudding at the end of their dialysis treatments 3-days per week for 12 weeks

: Ensure Plus

Will consume one Ensure Plus at the end of their dialysis treatments 3-days per week for 12 weeks

Primary outcome measure

  • Eligibility to randomization ratio [ Time Frame: Measured at the end of 12 weeks. ]
  • Recruitment rate [ Time Frame: 12 months ]
  • Follow up rate [ Time Frame: Measured at the end of 12 weeks. ]
  • Adherence to Intervention [ Time Frame: Measured at the end of12 weeks ]

Central Contacts and Locations

Central contacts

Navdeep Tangri, MD, PhD

2046313834ntangri@sogh.mb.ca

Tahmina Rahman, MSc

2046313834trahman2@sogh.mb.ca

Locations

Seven Oaks General Hospital

Recruiting

Winnipeg, Manitoba, Canada, R2V 3M3

Contacts

Navdeep Tangri, PhD, MD

204 631-3834ntangri@sogh.mb.ca

Rebecca Mollard, PhD

204 631-3834rmollard@sogh.mb.ca

Principal Investigator:

Navdeep Tangri, PhD, MD

Health Science Centre

Recruiting

Winnipeg, Manitoba, Canada, R3A 1R9

Contacts

Navdeep Tangri, PhD

204-631-3834ntangri@sogh.mb.ca

Rebecca Mollard, PhD

204-631-3834rmollard@sogh.mb.ca

Principal Investigator:

Navdeep Tangri, PhD

More Information

Sponsor

Seven Oaks Hospital Chronic Disease Innovation Centre

Last update posted

Apr 22, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Seven Oaks Hospital Chronic Disease Innovation Centre on 2026-04-22.